Shailendra Giri Selected Research

AICA ribonucleotide (ZMP)

1/2020	AMP-Activated Protein Kinase Restricts Zika Virus Replication in Endothelial Cells by Potentiating Innate Antiviral Responses and Inhibiting Glycolysis.
12/2016	5-Aminoimidazole-4-carboxamide ribonucleoside-mediated adenosine monophosphate-activated protein kinase activation induces protective innate responses in bacterial endophthalmitis.
1/2014	Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.
8/2006	5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction.
8/2006	AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model.
11/2005	5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase.
7/2005	5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shailendra Giri Research Topics

Disease

17	Neoplasms (Cancer) 03/2022 - 11/2005
14	Inflammation (Inflammations) 05/2022 - 05/2004
14	Ovarian Neoplasms (Ovarian Cancer) 03/2022 - 05/2011
12	Multiple Sclerosis 05/2022 - 01/2004
7	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2022 - 01/2004
6	Demyelinating Diseases (Demyelinating Disease) 05/2022 - 05/2002
6	Globoid Cell Leukodystrophy (Krabbe Disease) 06/2008 - 05/2002
4	Disease Progression 01/2022 - 12/2015
4	Brain Ischemia (Cerebral Ischemia) 01/2007 - 05/2004
3	Endophthalmitis (Ophthalmia) 01/2021 - 12/2016
3	Bacterial Infections (Bacterial Infection) 01/2021 - 01/2019
3	Infections 01/2021 - 06/2010
3	Ovarian Epithelial Carcinoma 01/2017 - 08/2014
3	Glioma (Gliomas) 01/2014 - 05/2002
3	Stroke (Strokes) 05/2006 - 05/2004
2	Virus Diseases (Viral Diseases) 01/2021 - 06/2010
2	Eye Infections 01/2020 - 12/2016
2	Zika Virus Infection 01/2020 - 01/2018
2	Autoimmune Diseases (Autoimmune Disease) 01/2019 - 06/2009
2	Ataxia (Dyssynergia) 01/2018 - 11/2014
2	Cognitive Dysfunction 01/2018 - 02/2015
2	Carcinoma (Carcinomatosis) 04/2016 - 01/2014
2	Adrenoleukodystrophy (Adrenoleukodystrophy, X-Linked) 01/2016 - 02/2014
2	Peroxisomal Disorders (Peroxisomal Disorder) 01/2016 - 02/2014
2	Obesity 07/2012 - 08/2006
2	Astrocytoma (Pilocytic Astrocytoma) 02/2012 - 11/2003
1	COVID-19 01/2021
1	Cytokine Release Syndrome 01/2021
1	Leukemia 01/2019
1	Hematoma 10/2018
1	Choroideremia 01/2018
1	Dengue (Dengue Fever) 01/2018
1	Japanese Encephalitis 01/2018
1	Central Nervous System Diseases (CNS Diseases) 01/2016

Drug/Important Bio-Agent (IBA)

10	Metformin (Glucophage)FDA LinkGeneric 03/2022 - 06/2009
8	AMP-Activated Protein KinasesIBA 01/2016 - 11/2005
7	AICA ribonucleotide (ZMP)IBA 01/2020 - 07/2005
7	Pharmaceutical PreparationsIBA 03/2016 - 11/2005
7	CytokinesIBA 01/2016 - 05/2002
6	Fatty Acids (Saturated Fatty Acids)IBA 04/2021 - 01/2014
5	Proteins (Proteins, Gene)FDA Link 01/2016 - 11/2005
5	Psychosine (Galactosylsphingosine)IBA 06/2008 - 05/2002
4	Biomarkers (Surrogate Marker)IBA 05/2022 - 03/2015
4	LipidsIBA 04/2021 - 08/2006
4	Retinaldehyde (Retinal)IBA 01/2021 - 12/2016
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2015 - 01/2014
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2014 - 05/2002
3	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 08/2006
3	NF-kappa B (NF-kB)IBA 12/2016 - 11/2003
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2015 - 08/2014
3	S-NitrosoglutathioneIBA 01/2014 - 02/2005
2	Deoxyglucose (2 Deoxy D glucose)IBA 01/2022 - 01/2020
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2020
2	Acetyl-CoA CarboxylaseIBA 01/2020 - 12/2016
2	Tyrosine (L-Tyrosine)FDA Link 01/2019 - 01/2014
2	Phosphotransferases (Kinase)IBA 12/2016 - 08/2014
2	Adenosine Monophosphate (AMP)IBA 12/2016 - 08/2014
2	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2016 - 06/2005
2	ceric oxide (cerium dioxide)IBA 03/2016 - 01/2013
2	Interleukin-17 (Interleukin 17)IBA 01/2016 - 11/2014
2	Adenosine Triphosphate (ATP)IBA 01/2016 - 01/2015
2	Drinking WaterIBA 05/2015 - 05/2011
2	Insulin (Novolin)FDA Link 05/2015 - 08/2014
2	LeptinIBA 05/2015 - 08/2014
2	Sirtuin 1IBA 08/2014 - 07/2012
2	AdipokinesIBA 07/2014 - 08/2006
2	Cisplatin (Platino)FDA LinkGeneric 01/2014 - 05/2011
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2006 - 07/2005
2	Oxidoreductases (Dehydrogenase)IBA 09/2006 - 01/2004
2	Coenzyme A (CoA)IBA 09/2006 - 01/2004
2	Lovastatin (Mevacor)FDA LinkGeneric 07/2005 - 01/2004
2	Free RadicalsIBA 06/2005 - 05/2004
2	beta-Galactosidase (Lactaid)IBA 09/2002 - 05/2002
1	Eicosapentaenoic AcidIBA 03/2022
1	TransferasesIBA 11/2021
1	Glutamine (L-Glutamine)FDA Link 11/2021
1	dihydrolipoamideIBA 11/2021
1	Aromatic Amino Acids (Aromatic Amino Acid)IBA 10/2021
1	itaconic acidIBA 01/2021
1	Phenylalanine (L-Phenylalanine)FDA Link 01/2019
1	Tryptophan (L-Tryptophan)FDA Link 01/2019
1	cytotropic heterogeneous molecular lipid (CHML)IBA 01/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2017
1	Oxygen (Dioxygen)IBA 01/2017
1	Protein Kinases (Protein Kinase)IBA 12/2016
1	Nonesterified Fatty Acids (NEFA)IBA 04/2016
1	Messenger RNA (mRNA)IBA 04/2016
1	Folic Acid (Vitamin M)FDA LinkGeneric 03/2016
1	Protein Isoforms (Isoforms)IBA 03/2016
1	MicroRNAs (MicroRNA)IBA 03/2016
1	Member 1 Subfamily D ATP Binding Cassette TransporterIBA 01/2016
1	Interleukin-23 (Interleukin 23)IBA 01/2016
1	resolvin D1IBA 12/2015
1	Carboplatin (JM8)FDA LinkGeneric 05/2015

Therapy/Procedure

9	Therapeutics 03/2022 - 01/2004
3	Drug Therapy (Chemotherapy) 01/2017 - 05/2015
3	Oral Administration 12/2015 - 01/2007
2	Ischemic Postconditioning 10/2018 - 02/2015
2	Caloric Restriction 05/2015 - 08/2014
1	Immunotherapy 11/2021